Suppr超能文献

与仅因海洛因入院治疗的患者相比,因海洛因和甲基苯丙胺入院治疗的患者的特征和医疗保健事件。

Characteristics and health care events of patients admitted to treatment for both heroin and methamphetamine compared to patients admitted for heroin only.

作者信息

El Ibrahimi Sanae, Hallvik Sara, Johnston Kirbee, Leichtling Gillian, Korthuis P Todd, Chan Brian, Hartung Daniel M

机构信息

Comagine Health, 650 NE Holladay St. #1700, Portland, OR 97232, USA; University of Nevada, Las Vegas/School of Public Health, 4505 S Maryland Pkwy, Las Vegas, NV 89154, USA.

Comagine Health, 650 NE Holladay St. #1700, Portland, OR 97232, USA.

出版信息

J Subst Abuse Treat. 2022 Jan;132:108615. doi: 10.1016/j.jsat.2021.108615. Epub 2021 Aug 31.

Abstract

INTRODUCTION

Co-occurring heroin and methamphetamine use is a growing public health problem. This study assessed the characteristics of Medicaid patients admitted to substance use disorder (SUD) treatment programs for heroin and methamphetamine use compared with patients admitted for heroin only.

METHODS

The study identified patients who entered treatment for heroin and methamphetamine and those admitted for heroin only between 2014 and 2017 from the Oregon Treatment Episode Data Set linked with Medicaid enrollment, and medical and pharmacy claims. We used a cross-sectional design to compare demographics, type of treatment, and substance use characteristics between the two groups. We used logistic regression models to assess differences in the odds of opioid-related and all-cause adverse events.

RESULTS

Among the 3802 study sample, 2004 (53%) were admitted for both heroin and methamphetamine use. The heroin and methamphetamine group were more likely to be younger, female, White or American Indian/Alaska Native; and had more comorbidities than patients admitted for heroin only. Patients admitted for heroin and methamphetamine treatment were less likely to receive any medication for opioid use disorder (MOUD) (56% vs 75%, p < 0.001) and received fewer days of MOUD treatment (mean 188 vs. 265 days, p < 0.001) compared to the heroin only group. The heroin and methamphetamine group were more likely to receive buprenorphine (28.1% vs 24.2%) and less likely to receive methadone (39.9% vs 62.5%). The heroin and methamphetamine group began use at a younger age, used and injected more frequently than those admitted for heroin only. Patients treated for heroin and methamphetamine had 17% lower odds of OUD-related adverse events (aOR 0.83; 95% CI 0.70-0.99) and 52% higher odds of all-cause adverse events (aOR 1.52; 95% CI 1.14-2.03) relative to the heroin only group.

CONCLUSION

Patients admitted for both heroin and methamphetamine reported greater addiction severity (more frequent use, earlier onset of use, and injection use), yet less commonly received MOUD compared to those who were admitted for heroin only. These findings indicate substantial missed opportunities for MOUD treatment even among people who successfully engage with the SUD treatment system.

摘要

引言

海洛因和甲基苯丙胺同时使用是一个日益严重的公共卫生问题。本研究评估了因使用海洛因和甲基苯丙胺而入住物质使用障碍(SUD)治疗项目的医疗补助患者的特征,并与仅因使用海洛因而入院的患者进行比较。

方法

该研究从与医疗补助登记以及医疗和药房报销记录相关联的俄勒冈治疗事件数据集里,识别出2014年至2017年间因海洛因和甲基苯丙胺接受治疗的患者以及仅因海洛因而入院的患者。我们采用横断面设计来比较两组患者的人口统计学特征、治疗类型和物质使用特征。我们使用逻辑回归模型来评估阿片类药物相关不良事件和全因不良事件发生几率的差异。

结果

在3802名研究样本中,2004名(53%)因同时使用海洛因和甲基苯丙胺而入院。与仅因海洛因而入院的患者相比,同时使用海洛因和甲基苯丙胺的患者更可能年轻、为女性、白人或美洲印第安人/阿拉斯加原住民;且合并症更多。与仅因海洛因而入院的患者相比,因海洛因和甲基苯丙胺接受治疗的患者接受阿片类物质使用障碍(MOUD)药物治疗的可能性更低(56%对75%,p<0.001),且接受MOUD治疗的天数更少(平均188天对265天,p<0.001)。同时使用海洛因和甲基苯丙胺的患者更可能接受丁丙诺啡治疗(28.1%对24.2%),而接受美沙酮治疗的可能性更低(39.9%对62.5%)。与仅因海洛因而入院的患者相比,同时使用海洛因和甲基苯丙胺的患者开始使用毒品的年龄更小,使用和注射频率更高。相对于仅因海洛因而入院的患者,因海洛因和甲基苯丙胺接受治疗的患者发生与阿片类物质使用障碍相关不良事件的几率低17%(调整后比值比[aOR]0.83;95%置信区间[CI]0.70 - 0.99),发生全因不良事件的几率高52%(aOR 1.52;95% CI 1.14 - 2.03)。

结论

与仅因海洛因而入院的患者相比,因同时使用海洛因和甲基苯丙胺而入院的患者报告的成瘾严重程度更高(使用更频繁、开始使用年龄更早且有注射使用情况),但接受MOUD治疗的情况却更不常见。这些发现表明,即使在成功参与SUD治疗系统的人群中,MOUD治疗也存在大量错失的机会。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验